Laura S Kerkmeijer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7599190/publications.pdf

Version: 2024-02-01

1684188 1372567 14 111 5 10 citations g-index h-index papers 14 14 14 247 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
2	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial. EuroIntervention, 2019, 15, 603-606.	3.2	11
3	1-Year Clinical Outcomes of AllÂComersÂTreated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 820-830.	2.9	10
4	Threeâ€year clinical outcomes after dualâ€therapy COMBO stent placement: Insights from the REMEDEE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 342-347.	1.7	8
5	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	1.7	6
6	Final fiveâ€year results of the REMEDEE Registry: Realâ€world experience with the dualâ€therapy COMBO stent. Catheterization and Cardiovascular Interventions, 2020, 98, 503-510.	1.7	6
7	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drugâ€eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. Catheterization and Cardiovascular Interventions, 2020, 95, 89-96.	1.7	4
8	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. International Journal of Cardiology, 2020, 300, 93-98.	1.7	4
9	Sex differences in 1â€year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2021, 97, 797-804.	1.7	4
10	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 567-570.	0.8	3
11	Stent thrombosis in patients with drug-eluting stents and bioresorbable vascular scaffolds. The feared complication. Polish Archives of Internal Medicine, 2018, 128, 52-59.	0.4	2
12	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. Annals of Translational Medicine, 2017, 5, 261-261.	1.7	2
13	Scaffold Resorption Process Is Not the Achilles' Heel of the Absorb BVS. JACC Basic To Translational Science, 2020, 5, 630-631.	4.1	1
14	Threeâ€year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimusâ€eluting stent in routine PCI in patients with diabetes mellitus— AIDA subâ€study. Catheterization and Cardiovascular Interventions, 2020, 98, 713-720.	1.7	1